Skip to main content
SpringerLink
Log in

Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia

  • Originals
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Calcium carbonate has been successfully used as a phosphate binder in patients with chronic renal failure; however, a high frequency of hypercalcaemia has been reported. To study the effects of calcium carbonate preparations with different dissolution characteristics on the incidence of this side effect, we conducted a double-blind, crossover trial in 21 patients undergoing chronic haemodialysis. Aluminium hydroxide therapy was replaced with calcium carbonate. The subjects then randomly received either an enteric-coated or a gastric-coated preparation. Calcium carbonate (3.1–3.6 g/d) controlled serum phosphate concentrations as effectively as aluminium hydroxide (2.9 g/d). Concurrently, there was a significant rise in mean serum calcium and a fall in serum concentrations of both parathyroid hormone and osteocalcin, the latter suggesting a decrease in bone turnover. Overall, hypercalcaemic episodes developed in 9 patients (43%) and occurred at a considerable frequency (33 episodes per 100 patient-months) during treatment with the gastric-coated formulation. Following conversion to enteric-coated calcium carbonate (3.6 g/d) patients had fewer occurrences of hypercalcaemia (12 episodes per 100 patient-months,P<0.05) and, as compared to the gastric-coated preparation, increases in serum calcium >3.00 mmol/l were not observed at all. Hyperaluminaemia was regressive during therapy with calcium carbonate, but addition of small doses of aluminium hydroxide caused a large rise in serum aluminium concentrations after infusion of desferrioxamine, indicating an enhanced rate of absorption or aberrant compartmentalization of aluminium.

We conclude that calcium carbonate can control hyperphosphataemia in dialysis patients. However, undesirable hypercalcaemic episodes may occur, the frequency and severity of which can be lowered by the use of an enteric-coated preparation. Concomitant use of aluminium hydroxide and calcium carbonate should be restricted to patients in whom the degree of aluminium accumulation is monitored by serial desferrioxamine tests.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alfrey AC (1983) Aluminum. Adv Clin Chem 23:69–91

    Google Scholar 

  2. Alfrey AC, Sedman A, Chan YL (1985) The compartmentalization and metabolism of aluminum in uremic rats. J Lab Clin Med 105:227–233

    Google Scholar 

  3. Alon U, Davidai G, Bentur L, Berant M, Better OS (1986) Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 12:320–325

    Google Scholar 

  4. Andress DL, Ott SM, Maloney NA, Sherrard DJ (1985) Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468–473

    Google Scholar 

  5. Andress DL, Kopp JB, Maloney NA, Coburn JW, Sherrard DJ (1987) Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 316:292–296

    Google Scholar 

  6. Breuer J, Moniz C, Baldwin D, Parsons V (1987) The effect of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transplant 2:347–350

    Google Scholar 

  7. Canavese C, Thea A, Pacitti A, Salomone M, Mangiarotti G, Segoloni G, Stratta P, Gurioli L, Costantini S, Giordini R, Vercellone A (1989) Prevention and treatment of aluminum overload in uremic patients: long-term results. Clin Nephrol 31:169–174

    Google Scholar 

  8. Clark AGB, Oner A, Ward G, Turner C, Rigden SPA, Haycock GB, Chantler C (1989) Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 4:539–544

    Google Scholar 

  9. Feinfeld DA, Sherwood LM (1988) Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int 33:1049–1058

    Google Scholar 

  10. Fordtran JS, Locklear TW (1966) Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 11:503–521

    Google Scholar 

  11. Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M (1986) Calcium carbonate, an aluminium-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 29:S-114–S-119

    Google Scholar 

  12. Froment DPH, Molitoris BA, Buddington B, Miller N, Alfrey AC (1989) Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 36:978–984

    Google Scholar 

  13. Henrich WL, Hunt JM, Nixon JV (1984) Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 310:19–23

    Google Scholar 

  14. Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, Sherrerd DJ, Coburn JW (1986) Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 12:314–319

    Google Scholar 

  15. Ittel TH, Buddington B, Miller NL, Alfrey AC (1987) Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 32:821–826

    Google Scholar 

  16. Ittel TH, Kluge R, Sieberth HG (1988) Enhanced gastrointestinal absorption of aluminium in uraemia: time course and effect of vitamin D. Nephrol Dial Transplant 3:617–623

    Google Scholar 

  17. Ittel TH, Hofstädter F, Gladziwa U, Sieberth HG (1989) Reduced deposition of aluminium in trabecular bone of uraemic rats treated with dihydroxylated vitamin D metabolites. Nephrol Dial Transplant 4:957–965

    Google Scholar 

  18. Ittel TH, Griessner A, Sieberth HG (1990) Effect of lactate on the absorption and retention of aluminum in the remnant kidney rat model. Nephron (in press)

  19. Kaye M (1983) Oral aluminum toxicity in a non-dialyzed patient with renal failure. Clin Nephrol 20:208–211

    Google Scholar 

  20. Kaye M, Barber E, Vasilevsky M, Langer K (1989) Calcium-free dialyzate: development and applications. Clin Nephrol 31:132–138

    Google Scholar 

  21. Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z (1987) Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 28:222–226

    Google Scholar 

  22. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS (1989) Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690–695

    Google Scholar 

  23. Malberti F, Surian M, Mercantini F, Marchini M (1988) Effects of dialysate calcium concentration changes on plasma calcium and parathyroid hormone in dialysis patients treated with calcium carbonate as a phosphate binder. Nephrol Dial Transplant 3:565

    Google Scholar 

  24. Maynard JC, Cruz C, Kleerekoper M, Levin NW (1986) Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 104:358–361

    Google Scholar 

  25. Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J (1985) Comparison of 1αOH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39:309–315

    Google Scholar 

  26. Morinière PH, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine CH, Marie A, Leflon P, Roche D, Fournier A (1988) Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralization. Nephrol Dial Transplant 3:651–656

    Google Scholar 

  27. Morinière PH, Boudailliez B, Hocine CH, Belbrik S, Renaud H, Westeel PF, Cohen-Solal M, Fournier A (1989) Prevention of osteitis fibrosa, aluminium bone disease and soft tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium+Mg(OH)2 vs Al(OH)3±1alphaOHvitamin D3. Nephrol Dial Transplant 4:1045–1053

    Google Scholar 

  28. Morinière P, Cohen-Solal M, Bebrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL, Fournier A (1989) Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53:93–101

    Google Scholar 

  29. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V (1986) Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet I:880–882

    Google Scholar 

  30. Oe PL, Lips P, Van der Meulen J, De Vries PMJ, Van Bronswijk H, Donker AJM (1987) Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 28:180–185

    Google Scholar 

  31. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS (1986) The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30:753–759

    Google Scholar 

  32. Renaud H, Atik A, Hervé M, Morinière P, Hocine C, Belbrik S, Fournier A (1988) Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 48:28–32

    Google Scholar 

  33. Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J (1989) High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 4:105–109

    Google Scholar 

  34. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS (1989) Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110–1113

    Google Scholar 

  35. Schneider HW, Kulbe KD, Weber H, Streicher E (1986) In vitro and in vivo studies with a non-aluminum phosphate-binding compound. Kidney Int 29:S120-S123

    Google Scholar 

  36. Sedman AB, Wilkening GN, Warady BA, Lum GM, Alfrey AC (1984) Encephalopathy in childhood secondary to aluminum toxicity. J Pediatr 105:836–838

    Google Scholar 

  37. Sheikh MS, Ramirez A, Emmett M, Santa Ana C, Schiller LR, Fordtran JS (1988) Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium. J Clin Invest 81:126–132

    Google Scholar 

  38. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS (1989) Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 83:66–73

    Google Scholar 

  39. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J (1986) Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157–161

    Google Scholar 

  40. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J (1989) Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897–903

    Google Scholar 

  41. Smith AJ, Faugere MC, Abreo K, Fanti P, Julian B, Malluche HH (1986) Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6:275–283

    Google Scholar 

  42. Williams B, Vennegoor M, O'Nunan T, Walls (1989) The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure. Nephrol Dial Transplant 4:725–729

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik II, Rheinisch-Westfälische Technische Hochschule Aachen, Deutschland

    T. H. Ittel, C. Schäfer, H. Schmitt, U. Gladziwa & H. G. Sieberth

Authors
  1. T. H. Ittel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Gladziwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. G. Sieberth
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ittel, T.H., Schäfer, C., Schmitt, H. et al. Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 69, 59–67 (1991). https://doi.org/10.1007/BF01666818

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01666818

Key words

Search

Navigation